PREMATURE EJACULATION TREATMENT MARKET ANALYSIS

Premature Ejaculation Treatment Market- Insights

Ejaculation means discharging of semen from the body. Premature ejaculation (PE) also known as rapid ejaculation, premature climax or early ejaculation is a condition in which the ejaculation happens earlier than a man or his partner would like during a sexual intercourse. The main sign of PE is incapability to delay ejaculation for more than one minute after penetration. Mainly PE can be classified in two types, namely lifelong (primary) PE and acquired (secondary) PE.

Lifelong (primary) PE is a condition, which affects a male lifelong, nearly from the beginning of his first sexual encounter. Acquired (secondary) PE is a condition in which a male who has a normal sex life starts suffering from PE. The actual cause of PE is not known, however, it can caused due to some psychological and biological factors such as early sexual experiences, sexual abuse, poor body image, depression, anxiety, abnormal hormone levels, inherited traits, inflammation and infection of the prostate or urethra, and worrying about premature ejaculation.

Frequent launches and approvals of novel premature ejaculation treatment products is expected to drive growth of the market

Key players in the market are focusing on launching new products, which in turn is expected to aid in growth of the market. For instance, in 2012, Absorption Pharmaceuticals, LLC launched its Promescent, an over-the-counter lidocaine-based spray, indicated for premature ejaculation. Furthermore, in 2013, Absorption Pharmaceuticals, LLC received patent for its Promescent, for premature ejaculation (PE) from the U.S. Patent and Trademark Office. The launches of novel drugs, which are indicated for the treatment of premature ejaculation is expected to fuel growth of the global premature ejaculation treatment market in the near future.

The global premature ejaculation treatment market size was valued at US$ 1.5 Bn in 2017, and is expected to witness a CAGR of 8.7% over the forecast period (2018 – 2026).

Figure 1. Global Premature Ejaculation Treatment Market Share (%), By Region, 2022

To learn more about this report, request sample copy

Source: Coherent Market Insights Analysis (2018)

Increasing strategic collaborations for development of new diagnostic tools is expected to propel the market growth

Key players in the market are involved in strategic collaborations for the development of premature ejaculation treatment drugs. For instance, in 2012, Ampio Pharmaceuticals, Inc. entered in a strategic agreement with Ethypharm S.A. for the manufacturing of Zertane, Ampio's drug indicated for the treatment of premature ejaculation. In 2013, Absorption Pharmaceuticals LLC entered into a strategic collaboration with Kaiser Permanente for initiating clinical trial to evaluate the efficacy of Promescent lidocaine spray for men with premature ejaculation (PE). Such strategic collaborations by key players for the development, manufacturing, and evaluation of novel drugs is expected to fuel the global premature ejaculation treatment market growth.

Figure 2. North America Premature Ejaculation Treatment Market Share (%), By Country, 2022

To learn more about this report, request sample copy

Source: Coherent Market Insights Analysis (2018)

Furthermore, key players are involved in raising funds for the development of drugs and are focused on expanding its sales network, in order to increase their sales. For instance, in 2013, Absorption Pharmaceuticals LLC, a manufacturer of Promescent spray indicated for treatment of premature ejaculation, expanded its international sales team. In 2014, Vyrix Pharmaceuticals, Inc., a subsidiary of Aytu BioScience, raised around US$ 28.75 million. The company financed development of tramadol hydrochloride (Zertane), indicated for the treatment of premature ejaculation from these funds.

Increasing prevalence of premature ejaculation is expected to increase demand for premature ejaculation drugs. For instance, according to the data published by European Association of Urology in 2017, the prevalence rate of premature ejaculation in the U.S. was estimated to be 30% (18-29 years), 32% (30-39 years), 28% (40-49 years), and 55% (50-59 years). According to the same source, the prevalence rate of four sub-types of erectile dysfunction was were 2.3% (lifelong PE), 3.9% (acquired PE), 8.5% (natural variable PE), and 5.1% (premature-like ejaculatory dysfunction). Such high prevalence of premature ejaculation is expected to lead to high demand for its treatment drugs and drive premature ejaculation treatment market growth.

Launch of alternative treatment methods for premature ejaculation is expected to be a major factor, which can restrain the market growth. For instance, in May 2018, InnovaDerma PLC launched a device, Prolong. Prolong is a FDA approved device used in the treatment of premature ejaculation. Launches of such devices is expected to restrain growth of the global premature ejaculation treatment market

Key players operating in the premature ejaculation treatment market include Regent Pacific Group Limited, Menarini Group, Furiex Pharmaceuticals, Inc., Absorption Pharmaceuticals, LLC, Ampio Pharmaceuticals, Inc., Aytu BioScience, NeuroHealing Pharmaceuticals Inc., and Dong-A Pharmaceutical Co., Ltd.